Tagged with manufactu

Turkey The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses the persisting issues within the country’s pricing and reimbursement system and why localization policies have been a net gain for…

France Fresh from a management buyout and the establishment of Skyepharma as an independent company, Managing Director David Lescuyer charts the fully integrated French CDMO’s startling growth trajectory over the past five years and outlines how the firm is well positioned for further growth. Lescuyer also highlights some of the key…

Turkey As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp Haas discusses the company’s presence and strategy in international markets, how the firm is leveraging its three US FDA-approved and EU GMP-certified production…

Asia-Pacific The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of cannabis in Thailand; and the first Vietnamese coronavirus vaccine candidate’s Phase III trials.   Indonesia’s Kalbe Farma sales underwhelm investors…

Switzerland Stefan Berg, general manager of Pharmaplan, one of the leading pharma engineering partners in Europe, outlines the key trends in this area, including an expected investment boom in the coming years as European countries like Switzerland aim to localise their manufacturing and supply chains. Berg explains how Pharmaplan acts as…

Switzerland Merck Switzerland’s Christiane von der Eltz highlights the German firm’s recent big investments in Switzerland and how it forms a key part of Merck’s global research and manufacturing networks. von der Eltz also explains how Merck Switzerland managed to successfully navigate the numerous challenges brought about by the COVID-19 pandemic…

Dominican Republic The rise of the Dominican Republic as a regional medtech manufacturing hub might have come as a surprise to many, but not to the insiders and executives of the Central America & Caribbean healthcare industry. With several decades of economic growth and political stability, the country has positioned itself as…

Australia Regular PharmaBoardroom contributor Brendan Shaw outlines how his home country of Australia has so far successfully managed to avoid the worst of the COVID-19 pandemic, providing opportunities for the life sciences industry to invest in new facilities, research and development in a post-pandemic world.   Australia, the island continent A…

Switzerland Susanne Caspar, CEO at Swiss natural API producer Linnea, talks about her first few months in the company, the pharmaceutical industry’s growing embrace of natural ingredients, and why Linnea has made the move into cannabis API production.   2020 was defined by an increase in demand for dietary supplements because…

Switzerland Swiss-headquartered ADIENNE has made recent headlines after being announced as the first European company to manufacture Russia’s Sputnik V COVID-19 vaccine. President and Founder Antonio Francesco Di Naro explains how the company’s deal with the Russian Direct Investment Fund happened and some of the challenges related to the manufacturing process.…

Switzerland In the last month alone, CDMO giant Lonza has announced three major upgrades to its manufacturing footprint in Visp, Western Switzerland: a huge expansion of its biologics capacity, new production lines for the manufacture of antibody-drug conjugates, and a ramping up of its workforce dedicated to the production of ingredients…

Singapore Lucas Chan, Scientific Founder and CSO of CellVec, a Singapore-based CDMO that specializes in the development and manufacture of viral vectors for clinical gene therapy, discusses how his company is helping companies with mature preclinical gene therapy projects wanting to progress into the clinic. Moreover, he discusses why Singapore is…